Olli Kallioniemi

University of Helsinki — Finland

Biochemistry, Genetics and Molecular Biology · Life Sciences

122h-index62.6kcitations941works0.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(134), Prostate Cancer Treatment and Research(113), Acute Myeloid Leukemia Research(73), Genomic variations and chromosomal abnormalities(72), Cancer, Lipids, and Metabolism(60)

Publications939 total

Validation of fibroblast activation protein and α‐smooth muscle actin as prognostic biomarkers in prostate cancer through <scp>AI</scp> ‐assisted image analysis of dual‐marker <scp>IHC</scp>
The Journal of Pathology Clinical Research·2025Open Access
Supplementary Tables from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
2025Open Access
Supplementary Figures from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
2025Open Access
Supplementary Data from Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
2025Open Access
Molecular profiling of ex vivo prostate cancer CAF models captures stromal heterogeneity and drug vulnerabilities
Cell Death Discovery·2025· 2 citedOpen Access
Single-cell multi-omics uncovers differentiation-dependent transcriptional programs shaping epigenetic subgroups in AML
Blood·2025
MALNC: a new mutant NPM1/IDH2R140 and PML-RARA-associated lncRNA with impact on AML cell proliferation, maturation and drug response
Cancer Gene Therapy·2025Open Access
Author response: Pathway activation model for personalized prediction of drug synergy
2025Open Access
Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer
Molecular Oncology·2025· 1 citedOpen Access
Pathway activation model for personalized prediction of drug synergy
eLife·2025Open Access
Author response: Pathway activation model for personalized prediction of drug synergy
2025Open Access
Pathway activation model for personalized prediction of drug synergy
2025Open Access
Mechanisms of chemotherapy failure in refractory/relapsed acute myeloid leukemia: the role of cytarabine resistance and mitochondrial metabolism
Cell Death and Disease·2025· 3 citedOpen Access
Abstract 6481: Multiplexed single-cell pharmacotranscriptomics and spatial tumor biology reveals targetable reciprocal cancer-stromal interactions in prostate cancer
Cancer Research·2025
Phosphodiesterase 3A modulators sensitize tumor cells to Bcl-xL and Bcl-2/Bcl-xL inhibitors
2025· 1 citedOpen Access
Author response: Pathway activation model for personalized prediction of drug synergy
2025Open Access
Pathway activation model for personalized prediction of drug synergy
2025Open Access
Abstract B026: Leveraging patient-derived models to identify novel treatment options in high-grade serous ovarian cancer
Cancer Research·2025
Abstract A017: Enhanced efficacy of anti-mesothelin CAR T cells in ovarian cancer through drug combinations: Impact of treatment kinetics, co-stimulatory domain, and donor variability
Cancer Research·2025
Author response for "Systematic profiling of cancer‐fibroblast interactions reveals drug combinations in ovarian cancer"
2025
page 1 of 47Next →

Frequent Co-authors

Juha Kononen(13), Anne Kallioniemi(9), Jorma Isola(9), Guido Sauter(8), Tapio Visakorpi(8), Joe W. Gray(6), Lukas Bubendorf(6), Minna Tanner(6), Krister Wennerberg(5), Peter Schraml(5), Ritva Karhu(5), Håkan Olsson(4), Oskar T. Johannsson(4), Jeffrey M. Trent(4), Pasi A. Koivisto(4), Teuvo L.J. Tammela(4), Henrik Edgren(4), Kimmo Porkka(4), Caroline A. Heckman(4), Holger Moch(4)